Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy.
about
Cardiac cachexia: hic et nuncPathophysiology of anorexia in the cancer cachexia syndromeDistinct behaviour of sorafenib in experimental cachexia-inducing tumours: the role of STAT3Muscle wasting: an overview of recent developments in basic research.Using AAV vectors expressing the β2-adrenoceptor or associated Gα proteins to modulate skeletal muscle mass and muscle fibre size.Clinical management of chronic obstructive pulmonary disease patients with muscle dysfunction.Cancer cachexia syndrome: pathogenesis, diagnosis, and new therapeutic options.Cancer cachexia, recent advances, and future directions.Cancer-induced muscle wasting: latest findings in prevention and treatment.Update on Management of Cancer-Related Cachexia.A multifactorial anti-cachectic approach for cancer cachexia in a rat model undergoing chemotherapy.Sarcopenia in gastric cancer: when the loss costs too much.Understanding tumor anabolism and patient catabolism in cancer-associated cachexiaFormoterol in the treatment of experimental cancer cachexia: effects on heart functionComplete reversal of muscle wasting in experimental cancer cachexia: Additive effects of activin type II receptor inhibition and β-2 agonist.Modulating Metabolism to Improve Cancer-Induced Muscle Wasting.
P2860
Q26744140-0642CEEE-BAF2-49B2-B86B-6FE7366AAF59Q26775294-3D4612C5-69C5-4D55-9E99-F3CE7CE14C30Q28542391-772075E6-E5B7-4249-A8B8-47CB4DFA155AQ34156942-32AC2577-405C-477E-A0F4-0AB7893AF32EQ36682199-089EBC5F-4906-40D8-B1C1-237B7AEADEA4Q37528272-8B312B95-E56D-4996-A2C0-33F0F500226CQ38290238-85E49AC5-35AB-40EB-9466-F4350AEBD8D2Q38393457-8833ACD0-E318-4927-8DD9-D000E4E9B3AEQ38681113-432DEA92-B45D-405F-BDF2-63A3E965A684Q38990581-F539277C-9192-4A17-8458-2C632FA19382Q39218137-FE58BCDA-763E-4827-94DF-BCB3800F3B48Q39287062-F5A6BAD1-8378-4A86-9FCC-DB2027011589Q39339489-3DF0793D-B18D-4884-9D6F-385D9D9B2D24Q42062172-12169F32-CACD-4DD0-A6C7-830A89305852Q46635433-63006F82-9617-483D-A53F-DD31553F8D06Q55301138-D1D41B4D-FBDB-467C-AB68-B0B1EC9A0D86
P2860
Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Phase I/II trial of formoterol ...... ents with advanced malignancy.
@en
Phase I/II trial of formoterol ...... ents with advanced malignancy.
@nl
type
label
Phase I/II trial of formoterol ...... ents with advanced malignancy.
@en
Phase I/II trial of formoterol ...... ents with advanced malignancy.
@nl
prefLabel
Phase I/II trial of formoterol ...... ents with advanced malignancy.
@en
Phase I/II trial of formoterol ...... ents with advanced malignancy.
@nl
P2093
P2860
P50
P1476
Phase I/II trial of formoterol ...... ents with advanced malignancy.
@en
P2093
A MacDonald
K C H Fearon
N A Stephens
R J E Skipworth
P2860
P2888
P304
P356
10.1007/S00520-013-2081-3
P577
2014-01-04T00:00:00Z